{"id":"W2607270289","doi":"10.1007/s00280-017-3287-8","title":"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Amgen","keywords":"Carfilzomib; Medicine; Multiple myeloma; Pharmacokinetics; End stage renal disease; Stage (stratigraphy); Oncology; Disease; Internal medicine; Intensive care medicine; Proteasome inhibitor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001881015,0.0002557486,0.0004962676,0.0001047104,0.0002510218,0.00005518744,0.0001886911,0.00006143682,0.0003633871],"category_scores_gemma":[0.00002504281,0.000201045,0.00001310055,0.00007148693,0.00043576,0.0002713928,0.0001544517,0.0002078164,2.645606e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000702947,"about_ca_system_score_gemma":0.0001279154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003879103,"about_ca_topic_score_gemma":0.0001356097,"domain_scores_codex":[0.9985122,0.0001308755,0.0002772048,0.0005119113,0.0002000014,0.0003677828],"domain_scores_gemma":[0.9988048,0.0000844734,0.0001920207,0.0002909023,0.0001179198,0.0005098487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07258107,0.01120684,0.798467,0.0001700108,0.0004915436,0.0002267435,0.0009701958,0.000001837093,0.03705838,0.00000402385,0.00007474993,0.07874764],"study_design_scores_gemma":[0.2306223,0.009212991,0.7402699,0.00006870278,0.0002396768,0.000003079854,0.00009531422,0.0008003764,0.01682607,0.000006726133,0.001640187,0.0002146655],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958524,0.0007902375,0.000004948208,0.0004056611,0.00007034068,0.002488334,0.0002922414,0.00001258373,0.00008326495],"genre_scores_gemma":[0.9975277,0.001298053,0.0001858981,0.0003990249,0.00006917432,0.0001707361,0.00006147029,0.00003627573,0.0002516219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1580412,"threshold_uncertainty_score":0.8198377,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05407738287008189,"score_gpt":0.3948468544672407,"score_spread":0.3407694715971588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}